No RUSH Fees For Expedited Hydroxychloroquine Testing

by | Mar 19, 2020 | covid19, Eagle Updates

In an effort to expedite treatment of COVID-19 patients, Eagle is offering rush Potency testing of Hydroxychloroquine at the standard rate with no additional rush fee.

According to a study by a group of French Researchers released on March 17, 2020, the drug which is normally utilized in treating Malaria has “been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients.”(1)

On March 19, 2020 President Trump, together with the White House Coronavirus Task Force announced “encouraging early results” in relation to COVID-19 patient response for the drug. “We’re going to be able to make that drug available almost immediately, and that’s why the FDA has been so great [and have] gone through the approval process.”

We at Eagle are proud to offer potency testing of this product’s formulas without customary rush fees. Eagle is dedicated to patient safety and encourages compounding pharmacists who will engage in the preparation of Hydroxychloroquine to take advantage of the complimentary rush service. Our goal is ensuring the safety of compounded medications and providing early access to results for COVID-19 treatments. For more information, contact us at 800-745-8916.


  1. Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. International Journal of Antimicrobial Agents – In Press 17 March 2020 – DOI : 10.1016/j.ijantimicag.2020.105949


Who We Are

Eagle consultants and scientists are helping compounding facilities implement successful quality systems. Our team has over 200 years of combined experience in the FDA-regulated pharmaceutical industry and can provide guidance in establishing the systems and processes that will help facilities producing compounded medications meet and exceed regulatory expectations. Follow the link below to learn more about our consulting services.

Eagle Analytical